Literature DB >> 23365164

An unusual cause of severe persistent neutropenia in a child with nephrotic syndrome.

Archana A Kshirsagar1, Christopher J D Reid, Jayanthi Alamelu, Manish D Sinha.   

Abstract

A 5-year-old boy presented with neutropenia 9 weeks following the administration of rituximab for management of his steroid-dependent nephrotic syndrome. Extensive investigations failed to identify any underlying cause. In keeping with adult reports, rituximab was thought to be the likely cause for this 'late-onset' neutropenia (LOP). He was treated successfully with granulocyte-colony-stimulating factor. Patients treated with rituximab need to be carefully monitored for LOP.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23365164      PMCID: PMC3604382          DOI: 10.1136/bcr-2012-007958

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Neutropenia in patients treated with rituximab.

Authors:  Eric Voog; Franck Morschhauser; Philippe Solal-Céligny
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

2.  Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center.

Authors:  E Besada; W Koldingsnes; J Nossent
Journal:  QJM       Date:  2012-02-01

Review 3.  Rituximab-associated neutropenia.

Authors:  Kieron Dunleavy; Kevin Tay; Wyndham H Wilson
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

4.  Rituximab efficiency in children with steroid-dependent nephrotic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Marie-Alice Macher; Chantal Loirat; Valérie Guérin; Hervé Watier; Michel Peuchmaur; Véronique Baudouin; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2010-03-18       Impact factor: 3.714

5.  Severe hematological side effects following Rituximab therapy in children.

Authors:  Sophie Larrar; Corinne Guitton; Marjolaine Willems; Brigitte Bader-Meunier
Journal:  Haematologica       Date:  2006-08       Impact factor: 9.941

6.  Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report.

Authors:  Ashima Gulati; Aditi Sinha; Stanley C Jordan; Pankaj Hari; Amit K Dinda; Sonika Sharma; Rajendra N Srivastava; Asha Moudgil; Arvind Bagga
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-26       Impact factor: 8.237

Review 7.  Nephrotic syndrome and rituximab: facts and perspectives.

Authors:  Dieter Haffner; Dagmar-Christiane Fischer
Journal:  Pediatr Nephrol       Date:  2009-06-04       Impact factor: 3.714

8.  Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children.

Authors:  Koichi Kamei; Shuichi Ito; Kandai Nozu; Shuichiro Fujinaga; Makiko Nakayama; Mayumi Sako; Mari Saito; Maki Yoneko; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2009-05-07       Impact factor: 3.714

9.  Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.

Authors:  Vincent Guigonis; Aymeric Dallocchio; Véronique Baudouin; Maud Dehennault; Caroline Hachon-Le Camus; Mickael Afanetti; Jaap Groothoff; Brigitte Llanas; Patrick Niaudet; Hubert Nivet; Natacha Raynaud; Sophie Taque; Pierre Ronco; François Bouissou
Journal:  Pediatr Nephrol       Date:  2008-05-09       Impact factor: 3.714

Review 10.  Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.

Authors:  Martin Bitzan; Mark Anselmo; Lucy Carpineta
Journal:  Pediatr Pulmonol       Date:  2009-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.